Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
CONCLUSION: Neoadjuvant FOLFIRINOX followed by CRT for middle and lower rectal cancer is feasible, tolerable with satisfactory sphincter preservation rate. <br />.
PMID: 32592369 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Endoscopy | Lower Endoscopy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Rectal Cancers